SciSparc Ltd aims to develop unique treatments to cure central nervous system disorders in 2022.
SciSparc Ltd. (NASDAQ: SPRC) is a clinical-stage pharmaceutical company primarily focused on the development of therapies for the treatment of disorders related to the central nervous system.
SciSparc Ltd consists of a team of experienced and professional scientists and senior managers. The company has raised more than $ 8 million from investors and institutions for its clinical programs.
In 2021, SciSparc Ltd added another feather to its charts when the company was granted two patents from the Australian Patent Office and Japan’s Basic Technology Patent Office from the pharmaceutical company. It consists of pharmaceutical compositions consisting of cannabinoids and N-acylethanolamines and several methods of preventing and treating cannabinoid conditions.
SciSparc Ltd is engaged in drug development programs SCI-110 for the treatment of Tourette’s syndrome and obstructive sleep apnea, SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorders and epilepsy.
Itzhak Shrem, Chairman of the Board of Directors of SciSparc, said: “We are extremely happy to have ended the year on a positive note. We have taken important steps. One of the most important is the listing of common shares on the Nasdaq Capital Market. “
In 2022, SciSparc Ltd plans to make progress in clinical programs in Tourette’s syndrome (TS), Alzheimer’s disease (AD) and restlessness and autism spectrum disorders (ASD). The pharmaceutical company is also considering expanding the partner’s network. They will also continue to spread awareness of unique treatments and technologies by showing them off at prestigious events around the world. The company also plans to strengthen the professional team and advisory board and increase its exposure to North American investors.
About SciSparc Ltd.
The clinical-stage pharmaceutical company is primarily focused on developing unique therapies to cure disorders of the central nervous system. SciSparc Ltd wishes to develop technologies using cannabinoid pharmaceuticals. The company is also interested in advancing clinical programs for AD and Agitation, TS, Pain and SE.
Warning: The products mentioned are THC free and / or compliant with the Farm Bill 2018.